Most Recent
Motorola has accused rival Hytera Communications of a "deliberate strategy" of filing late affidavits to throw Motorola off in an already highly contentious patent and copyright case over digital radio devices.
US financial services giant State Street Global Advisers has brought legal action against Maurice Blackburn Lawyers, alleging the law firm's plan to erect a copy of its Fearless Girl statue in Australia violates its trade mark and breaches consumer laws.
GM Holden has lost most of its case for design infringement against a company that imported and distributed spare car parts used to "up-spec" lower range Holden models, in the court's first test of the Designs Act's repair defence.
Mylan has appealed a ruling invaliding claims of its cholesterol drug patent and dismissing its patent infringement case against Sun Pharma.
A judge has panned evidence put on by Fuchs Lubricants in a patent dispute with Quaker Chemical as "woefully inadequate" and "absolutely garbage", partially shooting down the firm's attempt to block discovery of allegedly privileged documents.
Poppy processor TPI Enterprises has agreed to stop selling seed from high codeine poppy plants while it defends a lawsuit by rival Tasmanian Alkaloids alleging TPI infringed two of its innovation patents for high codeine-concentrated poppy.
Railway technology company Wavetrain Systems has asked the court to bar a competitor started by its former CEO from making allegedly false claims about its patented rail safety devices to clients.
Clive Palmer is facing the music after riffing off Twisted Sister's 1980s anthem 'We're Not Gonna Take It' in his election campaign ads, with Universal Music lodging a copyright infringement case against the aspiring MP.
A judge that rejected a bid by Sanofi-Aventis for an injunction blocking rival Alphapharm from listing an insulin injector pen on the PBS erred in his consideration of the harm it would face, the drug giant has told the Full Federal Court.
Pharmaceutical giant Wyeth has shot down arguments by rival Merck Sharp & Dohme that its Prevnar 13 vaccine lacked inventiveness, saying during the closing submissions of a high-stakes patent trial that up until it developed the top-selling shot scientists thought there was a "ceiling" of 11 types of pneumococcal bacteria that could be included in a single vaccine.